Oddo BHF confirms its Outperform rating on OSE Immunotherapeutics shares, with an unchanged target price of 7 euros.

The analyst reports that the DSMB (Data Monitoring and Surveillance Board) of the CoTikiS phase 2 trial evaluating lusvertikimab in ulcerative colitis (UC) has voted in favor of continuing the study to completion.

We expect results from the induction phase (10 weeks of treatment) in December 2023, as well as maintenance results after 6 months of treatment at the end of H1 2024, two major catalysts for the company", says Oddo BHF.

According to the broker, the main drawback to its short-term investment thesis remains the limited financial visibility today at Q2 2024e, despite the implementation of an equity line.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.